Position in OCS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$5,476,985
+$4,562,899 QoQ
Shares Held
394,880
+762.7% QoQ
Ownership
0.711%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#16
of 59 holders
Holding Since
Mar 2023
4 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in OCS Over Time
Shares Held
Position Value (USD)
Derivatives in OCS
reported options exposure · as of Mar 31, 2023CallValue
$0
CallShares
36,056
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. OCS ranks #100 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
543,897 | $270,169,956 | |
| 2 | INCY |
Incyte Corp
|
1,310,154 | $148,519,056 | |
| 3 | RPRX |
Royalty Pharma plc
|
2,450,669 | $137,409,009 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
991,693 | $88,042,503 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
259,799 | $78,207,292 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
1,333,207 | $75,739,488 | |
| 7 | MANE |
Veradermics, Inc
|
585,560 | $71,988,746 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
1,298,946 | $61,102,419 |
All Filings in OCS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,476,985 | 394,880 | Shares | Other | 2026-08-13 | |
| 2025-12-31 | $914,086 | 45,773 | Shares | Other | 2026-02-13 | |
| 2025-06-30 | $393,110 | 20,253 | Shares | Other | 2025-08-13 | |
| 2023-03-31 OCSAW | — | 36,056 | Call | Other | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||